| Product Name | FBLN3 ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Fibulin 3 (FBLN3). No significant cross-reactivity or interference between Fibulin 3 (FBLN3) and analogues was observed. |
| Synonyms | EFEMP1; DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; EGF-Containing Fibulin-Like Extracellular Matrix Protein 1; Fibrillin-Like; Extracellular protein S1-5 |
| Method | Sandwich |
| Detection Range | 1.56-100ng/mL |
| Sensitivity | 0.64ng/mL |
| Target | FBLN3 |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Fibulin 3 (FBLN3). No significant cross-reactivity or interference between Fibulin 3 (FBLN3) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Urine And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | Q12805 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma;YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.;Role of fibulin-3 in lung cancer: In vivo and in vitro analyses;Discovery of new biomarkers for malignant mesothelioma;DIAGNOSIS OF CELL PROLIFERATIVE DISEASES;Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma;Value of plasma and pleural effusion fibulin-3 levels in the diagnosis of malignant pleural mesothelioma effusions;Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma;Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis;Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.;Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study ;HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients;Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational …;Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.;A Novel Panel of Serum Biomarkers for MPM Diagnosis.;Association of fibulin-3 concentrations with the presence and severity of knee osteoarthritis: A cross-sectional study;Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population;Placental protein 14 as a potential biomarker for diagnosis of preterm premature rupture of membranes;The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion;Fibulin-3 and other cartilage metabolism biomarkers in relationship to calprotectin (MRP8/14) and disease activity in rheumatoid arthritis patients treated with …;Prediction of pneumoconiosis by serum and urinary biomarkers in workers exposed to asbestos-contaminated minerals; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEF422Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
